Evidence map›Paper›PMID 39710991›Full record

ArticleBrain and behavior2024

Seasonal Variations in Triptan Prescription in Japan: A Nationwide Time-Series Analysis.

Muneto Tatsumoto, Koichi Hirata, Takeo Nakayama, Kentaro Yamato, Hiromi Sano, Lyo Inuyama

Abstract read
In one paragraph

Article in Brain and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Muneto TatsumotoHeadache Center, Dokkyo Medical University Hospital, Tochigi, Japan.ORCID 0000-0002-1950-0756
Koichi HirataDepartment of Neurology, Dokkyo Medical University, Tochigi, Japan.ORCID 0000-0002-6492-4734
Takeo NakayamaDepartment of Health Informatics, School of Public Health, Kyoto University, Kyoto, Japan.ORCID 0000-0002-7918-6252
Kentaro YamatoDepartment of Medical Affairs, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan.ORCID 0000-0002-5027-6289
Hiromi SanoDepartment of Medical Affairs, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan.ORCID 0000-0001-8550-8249
Lyo InuyamaDepartment of Medical Affairs, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan.ORCID 0009-0008-2229-6881

Funding

Otsuka Pharmaceuticals Co. Ltd, Tokyo, Japan
6 · The paper itself

Abstract

objectiveThis study aimed to investigate seasonal differences in migraine onset in Japan and associated trends in the prescription of triptan.

backgroundThe relationship between seasonal changes and the onset of migraine remains largely unknown.

methodsWe combined the large-scale medical claims data in Japan with city-level meteorological data presented by the Japan Weather Association. The study period was from January 2018 to December 2019. We included patients aged 18-74 years and diagnosed with migraine who had been prescribed triptans in 2018. Patients were categorized into four groups according to the seasons when they were prescribed medicines: winter (January-March), spring (April-June), summer (July-September), and autumn (October-December). Migraine onsets were defined by the time of triptan prescription. The least-square mean differences between the seasons were estimated with linear mixed-effects models for repeated measures, adjusting for the following covariates: sex, age, acute migraine medications, and medications for migraine prevention, comorbidities that can induce migraine, other comorbidities, and the estimated age of menopause in females.

resultsWe analyzed data of 12,986 patients in 2019 after triptan had been prescribed (female 74.1%). The mean age was 44.1 years. The mean number of amounts of prescriptions comprised 2.12 tablets/month in spring and summer, whereas there were only 2.09 tablets/month in autumn and 2.00 tablets/month in winter. The amount of triptan prescribed in winter was lower than in spring (β = -0.117; 95% confidence interval [CI]: -0.169 to -0.065).

conclusionThe study results suggest that seasons can have an impact on the onset of migraine; thus, clinicians may advise patients to take preventive actions, including self-care and drug therapies, from the winter stage. This should be done in order to reduce the number of migraine onsets in high-risk season (spring) regardless of region.

Indexed as

Migraine DisordersSeasonsTryptaminesAdolescentAdultAgedDrug PrescriptionsFemaleHumansJapanMaleMiddle AgedYoung AdultTryptaminesmigraineobservational studyseasonaltriptansweather

Identifiers

PMID39710991
PMCPMC11663837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.